Nirsevimab Demonstrates Lasting Efficacy in Infants Through First RSV Season
October 28th 2023The drug, marketed as Beyfortus, was approved by the FDA in July for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Read More
Pharmacies Can Utilize Medication Synchronization Programs to Help Improve Cash Flow
October 15th 2023Tiffany Capps, CPhT, pharmacy operations manager at Galloway-Sands Pharmacy in North Carolina and marketing communications manager at CPESN, discusses how med sync programs can help boost a pharmacy's bottom line.
Read More